Upload Avatar (500 x 500)
Qiu Rao
raoqiu1103@126.com
English, Chinese
Jiangsu
Nanjing University
Medical School
  • PhD: Not mentioned
  • Postdoctoral: Not mentioned
  • Visiting Scholar: Indiana University
  • Hosted 3 National Natural Science Foundation projects
  • Hosted 1 Jiangsu Provincial Natural Science Foundation project
  • Granted 9 national invention patents
  • Published over 100 papers, including 40 SCI papers
  • Not mentioned - Nanjing University - Doctoral Supervisor
  • Not mentioned - Nanjing Medical University - Master's Supervisor
  • Not mentioned - Eastern Theater General Hospital of PLA - Director of Pathology Department
  • Liu Zhihong Young Medical Award (2012)
  • Wu Bingquan Pathology Development Foundation Excellent Young Scholar Award (2013)
  • Golden Pen Award by Chinese Journal of Pathology (2015)
  • China Outstanding Young Pathologist Award (2016)
  • Jiangsu Province Medical New Technology Introduction Award First Prize (2017)
  • Jiangsu Province Oncology Medicine Second Prize (2018)
  • Jiangsu Medical Science and Technology Youth Science and Technology Award (2020)
Molecular Pathological Diagnosis
Urological Tumors
  • Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma, Fang R, Rao Q, 2021
  • Malignant melanotic Xp11 neoplasms exhibit a clinicopathologic spectrum and gene expression profiling akin to alveolar soft part sarcoma: a proposal for reclassification, Wang XT, Rao Q, 2020
  • Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum, Xia QY, Wang XT, Rao Q, 2020
  • Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH, Xia QY, Wang XT, Ye SB, Wang X, Li R, Shi SS, Fang R, Zhang RS, Ma HH, Lu ZF, Shen Q, Bao W, Zhou XJ, Rao Q, 2018
  • RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations, Wang XT, Xia QY, Ye SB, Rao Q, 2018
  • Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3, Xia QY, Wang XT, Rao Q, 2017
  • Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement, Xia QY, Rao Q, 2017
  • Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH, Xia QY, Wang XT, Ye SB, Wang X, Li R, Shi SS, Fang R, Zhang RS, Ma HH, Lu ZF, Shen Q, Bao W, Zhou XJ, Rao Q, 2018
  • SFPQ/PSF-TFE3 Renal Cell Carcinoma (RCC): A Clinicopathologic Study Emphasizing Extended Morphology and Reviewing the Differences between SFPQ-TFE3 RCC and the Corresponding Mesenchymal Neoplasm despite an Identical Gene Fusion, Wang XT, Xia QY, Ni H, Ye SB, Li R, Wang X, Shi SS, Zhou XJ, Rao Q, 2017
  • BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation, Xia QY, Zhan XM, Fan XS, Ye SB, Shi SS, Li R, Wei X, Wang X, Ma HH, Lu ZF, Zhou XJ, Rao Q, 2017
  • Xp11 translocation renal cell carcinomas (RCCs) with RBM10-TFE3 gene fusion demonstrating melanotic features and overlapping morphology with t(6;11) RCC: interest and diagnostic pitfall in detecting a paracentric inversion of TFE3, Qiu-yuan Xia, Xiao-tong Wang, Qiu Rao, 2017
  • Extended immunologic and genetic lineage of mammary analogue secretory carcinoma of salivary glands, Ni H, Zhang XP, Wang XT, Xia QY, Lv JH, Wang X, Shi SS, Li R, Zhou XJ, Rao Q, 2016
  • Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas, Rao Q, Xia QY, Cheng L, Zhou XJ, 2016
  • Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum, Wang XT, Xia QY, Ni H, Wang ZY, Ye SB, Li R, Wang X, Lv JH, Shi SS, Ma HH, Lu ZF, Shen Q, Zhou XJ, Rao Q, 2016
  • PSF/SFPQ Is a Very Common Gene Fusion Partner in TFE3 Rearrangement-associated Perivascular Epithelioid Cell Tumors (PEComas) and Xp11 Translocation Renal Cancers: Clinicopathologic, Immunohistochemical, and Molecular Characteristics Suggesting Classification as a Distinct Entity, Rao Q, Shen Q, Xia QY, et al., 2015
  • TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum, Rao Q, Williamson SR, Zhang S, et al., 2013
  • Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization, Rao Q, Liu B, Cheng L, et al., 2012
  • Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers, Rao Q, Williamson SR, Lopez-Beltran A, et al., 2013
  • Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours, Rao Q, Xia QY, Wang ZY, et al., 2015
  • Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas, Rao Q, Cheng L, Xia QY, et al., 2013
Molecular Pathology Diagnosis Urology Tumors Cancer Genetics Research Oncology Pathology Autophagy

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.